Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK

Journal of Medicinal Chemistry

Volumn 50, Issue 19, 2007, Pages 4710-4720

  Kitagawa, Hideo ^a   Ozawa, Tomohiro ^a   Takahata, Sho ^a   Iida, Maiko ^a   Saito, Jun ^a   Yamada, Mototsugu ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[4 [4 [2 [3 (2,6 DICHLOROBENZYL) 2 METHYL 4 OXOPYRIDIN 1(4H) YL]ETHYL]PHENYL] 1H IMIDAZOL 2 YL]METHYL] 3 [6 (METHYLSULFONYL)BENZO[D]THIAZOL 2 YL]UREA; 4 PYRIDONE DERIVATIVE; DIAZABORINE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); IMIDAZOLE DERIVATIVE; PHENYLIMIDAZOLE DERIVATIVE; PROTEIN FABI; PROTEIN FABK; SODIUM 2 [4 [2 [[3 [5 (PYRIDIN 2 YLTHIO)THIAZOL 2 YL]UREIDO]METHYL] 1H IMIDAZOL 4 YL]PHENOXY]ACETATE; TRICLOSAN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HAEMOPHILUS INFLUENZAE; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZOTHIAZOLES; BINDING SITES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ESCHERICHIA COLI PROTEINS; FATTY ACIDS; HUMANS; IMIDAZOLES; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PYRIDONES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UREA;

EID: 34648833337     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0705354     Document Type: Article

References (45)

1. Voss, A.; Doebbeling, S. N. The worldwide prevalence of methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 1995, 5, 101-106.
2. Bax, R.; Mullan, N.; Verhoef, J. The millennium bugs - The need for and development of new antibacterials. Int. J. Antimicrob. Agents 2000, 16 (1), 51-9.
3. Setti, E. L.; Quattrocchio, L.; Micetich, R. G. Current approaches to overcome bacterial resistance. Drugs Future 1997, 22, 271-284.
4. Pearson, H. 'Superbug' hurdles key drug barrier. Nature 2002, 418, 469.
5. Clemett, D.; Markham, A. Linezolid. Drugs 2000, 59, 815-827.
6. Abbanat, D.; Macielag, M.; Bish, K. Novel antibacterial agents for the treatment of serious Gram-positive infections, Expert Opin. Invest. Drugs 2003, 12, 379-399.
7. Kara L. S.; Sarah M. M.; Jeffrey R. A. Tigecycline: A novel glycylcycline antiobiotic. Formulary 2005, Aug 1.
8. Payne, D. J.; Warren, P. V.; Holmes, D. J.; Ji, Y.; Lonsdale, J. T. Bacterial fatty-acid biosynthesis: A genomics-driven target for antibacterial drug discovery. Drug Discovery Today 2001, 6 (10), 537-544.
9. Heath, R. J.; White, S. W.; Rock, C. O. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 2001, 40 (6), 467-97.
10. Campbell, J. W.; Cronan, J. E., Jr. Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery. Annu. Rev. Microbiol. 2001, 55, 305-32.
11. Lai, C.-Y.; Cronan, J. E. β-Ketoacyl-acyl carrier protein synthase III (FabH) is essential for bacterial fatty acid synthesis. J. Biol. Chem. 2003, 278 (51), 51494-51503.
12. Revill, W. P.; Bibb, M. J.; Scheu, A.-K.; Kieser, H. J.; Hopwood, D. A. β-Ketoacyl acyl carrier protein synthase III (FabH) is essential for fatty acid biosynthesis in Streptomyces coelicolor A3(2). J. Bacteriol. 2001, 183 (11), 3526-3530.
13. Schujman, G. E.; Choi, K.-H.; Altabe, S.; Rock, C. O.; Mendoza, D. DE. Response of Bacillus subtilis to cerulenin and acquisition of resistance. J. Bacteriol. 2001, 183 (10), 3032-40.
14. Hoang, T. T.; Sullivan, S. A.; Cusick, J. K.; Schweizer, H. P. β-Ketoacyl acyl carrier protein reductase (FabG) activity of the fatty acid biosynthetic pathway is a determining factor of 3-oxo-homoserine lactone acyl chain lengths. Microbiol. 2002, 148, 3849-3856.
15. Tasdemir, D.; Lack, G.; Brun, R. Rüedi, P.; Scapozza, L.; Perozzo, R. Inhibition of Plasmodium falciparum fatty acid biosynthesis: Evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J. Med. Chem. 2006, 49 (17), 3345-3353.
16. Kimber, M. S.; Martin, F.; Lu, Y.; Houston, S.; Vedadi, M.; Dharamsi, A.; Fiebig, K. M.; Schmid, M.; Rock, C. O. The structure of (3R)-hydroxyacyl-acyl carrier protein dehydratase (FabZ) from Pseudomonas aeruginosa. J. Biol. Chem. 2004, 279 (50), 52593-52602.
17. Wang, H.; Cronan, J. E. Functional replacement of the FabA and FabB proteins of Escherichia coli fatty acid synthesis by Enterococcus faecalis FabZ and FabF homologues. J. Biol. Chem. 2004, 279 (33), 34489-34495.
18. Bergler, H.; Fuchsbichler, S.; Högenauer, G.; Turnowsky, F. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. Eur. J. Biochem. 1996, 242, 689-694.
19. Heath, R. J.; Li, J.; Roland, G. E.; Rock, C. O. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 2000, 275 (7), 4654-4659.
20. Heath, R. J.; Rock, C. O. Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli. J. Biol. Chem. 1996, 271 (4), 1833-1836.
21. Heath, R. J.; Rock, C. O. Inhibition of β-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. J. Biol. Chem. 1996, 271 (18), 10996-11000.
22. Bergler, H.; Wallner, P.; Ebeling, A.; leitinger, B.; Fuchsbichler, S.; Aschauer, H.; Kollenz, G.; Högenauer, G.; Turnowsky, F. Protein envM is the NADH-dependent enoyl-ACP reductase fabI of Escherichia coli. J. Biol. Chem. 1994, 269, 5493-5496.
23. Heath, R. J.; Rock, C. O. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 1995, 270, 26538-26542.
24. Rozwarski, D. A.; Grant, G. A.; Barton, D. H.; Jacobs, W. R., Jr.; Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998, 279 (5347), 98-102.
25. Baldock, C.; Rafferty, J. B.; Sedelnikova, S. E.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Hawkes, T. R.; Rice, D. W. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 1996, 274 (5295), 2107-10.
26. Levy, C. W.; Baldock, C.; Wallace, A. J.; Sedelnikova, S.; Viner, R. C.; Clough, J. M.; Stuitje, A. R.; Slabas, A. R.; Rice, D. W.; Rafferty, J. B. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase. J. Mol. Biol. 2001, 309 (1), 171-80.
27. McMurry, L. M.; Oethinger, M.; Levy, S. B. Triclosan targets lipid synthesis. Nature 1998, 394 (6693), 531-532.
28. Heath, R. J.; Yu, Y.-T.; Shapiro, M. A.; Olson, E.; Rock, C. O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 1998, 273, 30316-30320.
29. Levy, C. W.; Roujeinikova, A.; Sedelnikova, S.; Baker, P. J.; Stuitje, A. R.; Slabas, A. R.; Rice, D. W.; Rafferty, J. B. Molecular basis of triclosan activity. Nature 1999, 398 (6726), 383-384.
30. McMurry, L. M., McDermott, P. F., Levy, S. B. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents. Chemother. 1999, 43, 711-713.
31. Ward, W. H.; Holdgate, G. A.; Rowsell, S.; McLean, E. G.; Pauptit, R. A.; Clayton, E.; Nichols, W. W.; Colls, J. G.; Minshull, C. A.; Jude, D. A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N. J.; Britton, C. J.; Taylor, I. W. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 1999, 38 (38), 12514-25.
32. Stewart, M. J.; Parikh, S.; Xiao, G.; Tonge, P. J.; Kisker, C. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 1999, 290 (4), 859-865.
33. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; DeWolf, W. E., Jr.; Elkins, P. A.; Head, M. S.; Jakas, D. R.; Janson, C. A.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Payne, D. J.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Uzinskas, I. N.; Wallis, N. G.; Huffman, W. F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 2003, 46 (9), 1627-1635.
34. Miller, W. H.; Seefeld, M. A.; Newlander, K. A.; Uzinskas, I. N.; Burgess, W. J.; Heerding, D. A.; Yuan, C. C.; Head, M. S.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; Pearson, S. C.; Berry, V.; DeWolf, W. E., Jr.; Keller, P. M.; Polizzi, B. J.; Qiu, X.; Janson, C. A.; Huffman, W. F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 2002, 45 (15), 3246-3256.
35. Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; DeWolf, W. E., Jr.; Keller, P. M.; Qiu, X.; Janson, C. A.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Jaworski, D. D.; Slater-Radosti, C.; Huffman, W. F. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-Disubstituted 1,2,3,4-tetrahydropyrido[3,4- b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 2001, 11 (17), 2241-2244.
36. Ling, L. L.; Xian, J.; Ali, S.; Geng, B.; Fan, J.; Mills, D. M.; Arvanites, A. C.; Orgueira, H.; Ashwell, M. A.; Carmel, G.; Xiang, Y.; Moir, D. T. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob. Agents. Chemother. 2004, 48 (5), 1541-1547.
37. Heath, R. J.; Rock, C. O. A triclosan-resistant bacterial enzyme. Nature 2000, 406 (6792), 145-6.
38. Marrakchi, H.; Dewolf, W. E., Jr.; Quinn, C.; West, J.; Polizzi, B. J.; So, C. Y.; Holmes, D. J.; Reed, S. L.; Heath, R. J.; Payne, D. J.; Rock, C. O.; Wallis, N. G. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem. J. 2003, 370, 1055-62.
39. Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J.; Chen, E.; DeWolf, W. E.; Jr, Fosberry, A. P., Jr.; Greenwood, R.; Head, M. S.; Heerding, D. A.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.; Vaidya, K.; Wallis, N. G.; Winram, S. B.; Yuan, C. C.; Huffman, W. F. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents. Chemother. 2002, 46 (10), 3118-24.
40. Kitagawa, H.; Kumura, K.; Takahata, S.; Iida, M.; Atsumi, K. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase Fabl. Bioorg. Med. Chem. 2007, 15, 1106-1116.
41. Kitagawa, H.; Ozawa, T.; Takahata, S.; Iida, M. Phenylimidazole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK. Bioorg. Med Chem. Lett. 2007, in press.
42. Takahata, S.; Iida, M; Osaki, Y.; Saito, J.; Kitagawa, H.; Ozawa, T.; Yoshida, T., Hoshiko, S. AG205, a novel agent directed against FabK of Streptococcus pneumoniae. Antimicrob. Agents. Chemother. 2006, 50 (8), 2869-2871.
43. Saito, J.; Yamada, M.; Watanabe, T.; Kitagawa, H.; Takeuchi, Y. Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae. Acta Crystallogr. 2006, F62, 576-578.
44. Kitagawa, H.; Kumura, K.; Atsumi, K. A novel synthesis of 2,3-disubstituted-4-pyridones from 4-methoxypyridine. Chem. Lett. 2006, 35, 712.
45. Takahata, S.; Iida, M.; Yoshida, T.; Kumura, K.; Kitagawa, H.; Hoshiko, S. Discovery of 4-pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus. J. Antibiot. (Tokyo). 2007, 60, 123-128.